Shopping Cart
- Remove All
Your shopping cart is currently empty
JD-5037
🥰Excellent
Catalog No. T4453Cas No. 1392116-14-1
Alias JD 5037
JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.
JD-5037
🥰Excellent
Purity: 98.87%
Catalog No. T4453Alias JD 5037Cas No. 1392116-14-1
JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | 35 € | In Stock | |
| 2 mg | 50 € | In Stock | |
| 5 mg | 82 € | In Stock | |
| 10 mg | 135 € | In Stock | |
| 25 mg | 246 € | In Stock | |
| 50 mg | 369 € | In Stock | |
| 100 mg | 550 € | In Stock | |
| 1 mL x 10 mM (in DMSO) | 102 € | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "JD-5037"
2,3-Butanediol
T19094513-85-9
2,3-Butanediol, derived from the bioconversion of natural resources, holds significant potential for various industries, including chemical, cosmetics, agriculture, and pharmaceutical sectors.
- 38 €
Size
QTY
β-Caryophyllene
Cited
(−)-β-caryophyllene, (−)-trans-Caryophyllene, (-)-(E)-Caryophyllene
T911487-44-5
β-Caryophyllene ((-)-(E)-Caryophyllene) acts as an CB2 receptor agonist.
- 38 €
Size
QTY
CitedPregnenolone acetate
3β-Hydroxy-5-pregnen-20-one acetate
TC00191778-02-5
Pregnenolone acetate is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. It acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. It can protect the brain from cannabis intoxication
- 28 €
Size
QTY
Pregnenolone
Arthenolone, 3β-Hydroxy-5-pregnen-20-one
T0851145-13-1
Pregnenolone (Arthenolone) is an endogenous steroid hormone synthesized from cholesterol, used in the treatment of Alzheimer's disease.
- 42 €
Size
QTY
CB1 antagonist 2
AM4113
T14881614726-85-1
CB1 antagonist 2 (AM4113) is caimabinoid 1 (CB1) antagonist which inhibits CB1 in vivo with an IC50 of 25.5 nM.
- 28 €
Size
QTY
Drinabant
AVE-1625, AVE1625
T21861358970-97-5In house
Drinabant (AVE-1625) is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.
- 75 €
Size
QTY
CB2 modulator 1
T10696666261-80-9In house
CB2 modulator 1 is a potent CB2 modulator. It can be used for the research for immune disorders, osteoporosis, inflammation, renal ischemia.
- 28 €
Size
QTY
AM281 Cited
T2264202463-68-1
AM 281, a cannabinoid antagonist, reduces neurologic dysfunction and mortality rate after cecal ligation and puncture in rats.
- 73 €
Size
QTY
CitedOMDM-5
T12306616884-66-3
OMDM-5 is a selective anandamide cellular uptake (ACU)inhibitor(Ki of 4.8 μM).
- 84 €
Size
QTY
CB2 receptor agonist 2
ZINC72105556, 4-Quinolone-3-Carboxamide Furan CB2 Agonist
T220091314230-75-5In house
CB2 receptor agonist 2 (ZINC72105556) is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor, Ki = 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2.
- 112 €
Size
QTY
AM-1235
AM1235, AM 1235
T29930335161-27-8In house
AM-1235 is a potent and selective cannabinoid receptor CB1 agonist.
- 332 €
Size
QTY
CB1 inverse agonist 1
MRL-650
T10694852315-00-5In house
CB1 inverse agonist 1 (MRL-650) is an orally active and selective CB1 agonist. The IC50s for CB1 and CB2 are 7.5 nM and 4100 nM, respectively. CB1 inverse agonist 1 shows anorexigenic effects.
- 66 €
Size
QTY
Select Batch
Purity:98.87%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. |
| Targets&IC50 | CB1 receptor:1.5 nM |
| In vivo | JD5037, when administered at a dosage of 3 mg/kg/day intraperitoneally (i.p.), effectively induces uniform reductions in body weight and mitigates high-fat diet (HFD)-induced hyperglycemia, hepatic injury, and steatosis in obese Magel2-null mice. Likewise, oral administration of JD5037 (3 mg/kg/day, p.o.) significantly diminishes tumor size and eliminates tumors in DEN-treated mice. Moreover, JD5037 reduces anandamide (AEA) levels in hepatocellular carcinoma (HCC) samples from mice. |
| Animal Research | Mice: JD-5037 is formulated in vehicle (V; 1% Tween80, 4% DMSO, 95% Saline). Obese mice are treated chronically (28 d) with vehicle (V; 1% Tween80, 4% DMSO, 95% Saline), JD5037, or SLV319 at a dose of 3 mg/kg, i.p. Body weight and food intake are monitored daily. Mice are euthanized by cervical dislocation under anesthesia; the brain, hypothalamus, liver, and combined fat pads are removed, weighed, and snap-frozen, and trunk blood is collected for determining the endocrine and biochemical parameters |
| Alias | JD 5037 |
| Molecular Weight | 572.51 |
| Formula | C27H27Cl2N5O3S |
| Cas No. | 1392116-14-1 |
| Smiles | CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |
| Relative Density. | 1.40 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (87.33 mM)  | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy JD-5037 | purchase JD-5037 | JD-5037 cost | order JD-5037 | JD-5037 chemical structure | JD-5037 in vivo | JD-5037 formula | JD-5037 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.